» Articles » PMID: 32369957

The Protective Effects of 2'-Fucosyllactose Against O157 Infection Are Mediated by the Regulation of Gut Microbiota and the Inhibition of Pathogen Adhesion

Overview
Journal Nutrients
Date 2020 May 7
PMID 32369957
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

As the richest component in human milk oligosaccharides (HMOs), 2'-fucosyllactose (2'-FL) can reduce the colonization of harmful microbiota in vivo, thus lowering the risk of infection; however, the mechanism for this is still unclear. In this study, a model of O157 infection in healthy adult mice was established to explore the effect of 2'-FL intervention on O157 colonization and its protective effects on mice. The results showed that 2'-FL intake reduced O157 colonization in mice intestine by more than 90% ( < 0.001), and it also reduced intestinal inflammation, increased the content of fecal short-chain fatty acids, and enhanced intestinal barrier function. These beneficial effects were attributed to the increased expression of mucins such as (increased by more than 20%, p < 0.001), and inhibition of E. coli O157 cell adhesion (about 30% reduction, p < 0.001), and were associated with the modulation of gut microbiota composition. 2'-FL significantly increased the abundance of , a potential probiotic, which may represent the fundamental means by which 2'-FL enhances the expression of mucin and reduces the colonization of harmful bacteria. The current study may support the use of 2'-FL in the prevention of foodborne pathogen infections in human.

Citing Articles

Human milk oligosaccharides: bridging the gap in intestinal microbiota between mothers and infants.

Sun W, Tao L, Qian C, Xue P, Du S, Tao Y Front Cell Infect Microbiol. 2025; 14():1386421.

PMID: 39835278 PMC: 11743518. DOI: 10.3389/fcimb.2024.1386421.


2'-Fucosyllactose inhibits human norovirus replication in human intestinal enteroids.

Patil K, Ayyar B, Hayes N, Neill F, Bode L, Estes M J Virol. 2025; 99(2):e0093824.

PMID: 39791912 PMC: 11853015. DOI: 10.1128/jvi.00938-24.


2'-Fucosyllactose Inhibits Human Norovirus Replication in Human Intestinal Enteroids.

Patil K, Ayyar B, Neill F, Bode L, Estes M, Atmar R bioRxiv. 2024; .

PMID: 38853945 PMC: 11160698. DOI: 10.1101/2024.05.30.596597.


Ameliorating Effects of subsp. FB3-14 against High-Fat-Diet-Induced Obesity and Gut Microbiota Disorder.

Kou R, Wang J, Li A, Wang Y, Zhang B, Liu J Nutrients. 2023; 15(19).

PMID: 37836387 PMC: 10574542. DOI: 10.3390/nu15194104.


Gut Microbiota Metabolites Mediate Bax to Reduce Neuronal Apoptosis via cGAS/STING Axis in Epilepsy.

Zhai J, Wang C, Jin L, Liu F, Xiao Y, Gu H Mol Neurobiol. 2023; 61(12):9794-9809.

PMID: 37605097 DOI: 10.1007/s12035-023-03545-y.


References
1.
Asshauer K, Wemheuer B, Daniel R, Meinicke P . Tax4Fun: predicting functional profiles from metagenomic 16S rRNA data. Bioinformatics. 2015; 31(17):2882-4. PMC: 4547618. DOI: 10.1093/bioinformatics/btv287. View

2.
Ruiz-Palacios G, Cervantes L, Ramos P, Chavez-Munguia B, Newburg D . Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003; 278(16):14112-20. DOI: 10.1074/jbc.M207744200. View

3.
Salli K, Anglenius H, Hirvonen J, Hibberd A, Ahonen I, Saarinen M . The effect of 2'-fucosyllactose on simulated infant gut microbiome and metabolites; a pilot study in comparison to GOS and lactose. Sci Rep. 2019; 9(1):13232. PMC: 6744565. DOI: 10.1038/s41598-019-49497-z. View

4.
McCole D . IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis. 2014; 20(10):1829-49. PMC: 4357271. DOI: 10.1097/MIB.0000000000000090. View

5.
Weichert S, Jennewein S, Hufner E, Weiss C, Borkowski J, Putze J . Bioengineered 2'-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutr Res. 2013; 33(10):831-8. DOI: 10.1016/j.nutres.2013.07.009. View